Advertisement
Advertisement
U.S. Markets close in 5 hrs 36 mins
Advertisement
Advertisement
Advertisement
Advertisement

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.39+0.24 (+3.90%)
As of 10:23AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.15
Open6.16
Bid6.46 x 3100
Ask6.47 x 2900
Day's Range6.15 - 6.46
52 Week Range2.68 - 10.06
Volume257,735
Avg. Volume1,356,761
Market Cap459.516M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateFeb 24, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
  • GlobeNewswire

    Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

    XMT-1660 currently being studied in a Phase 1 trial enrolling patients with breast, endometrial and ovarian cancersCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-

  • GlobeNewswire

    Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at two upcoming investor conferences. Details are as follows: Morgan Stanley 20th Annual Global Healthcare ConferenceFormat: Fireside Chat Date/Time: Monday, Septembe

  • GlobeNewswire

    Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on September 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25

Advertisement
Advertisement